empoweringmuscleempoweringlives
As a leader in muscle biology research, we are dedicated to our mission of improving the lives of people confronting devastating diseases of impaired muscle function.
Cytokinetics to Announce Second Quarter Results on July 26, 2018
SOUTH SAN FRANCISCO, Calif. , July 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on July 26, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a...
READ MORE ›
Now Available | 2017 Annual Report
The enduring power of our science and the benefits of a diversified pipeline strategy came into focus during the past year. We now press forward with a solid foundation on which we are planning for a prosperous future.
als
People fighting amyotrophic lateral sclerosis have few treatment options; we are dedicated to changing the progression of this fatal disease.
Heart Failure
Heart failure death and disability rates continue to rise, despite current treatment options. With Amgen, we are developing a novel therapy that may improve cardiac performance in people with heart failure.
sma
People suffering from spinal muscular atrophy experience devastating loss of muscle function. With Astellas, we are working on a treatment that may enhance skeletal muscle performance in these and other patients.